Nafarelin Acetate

A synthetic decapeptide, similar to gonadorelin, analogue of natural luteinizing hormone releasing hormone (LHRH). Indicated in in vitro fertilization treatments before stimulation with exogenous gonadotropins for ovarian stimulation. Intranasal, subcutaneous or intravenous administration. It is also used in the treatment of endometriosis and  central precocious puberty,

At the date of the last update we did not find any published data on its excretion in breast milk.

Its high molecular weight  make it unlikely that significant amounts will transfer into breastmilk.

Due to its protein nature, it is inactivated in the gastrointestinal tract^{(Van Leusden 1994, Fraser 1993}), not being absorbed (practically zero oral bioavailability), which hinders its transfer into the infant's plasma from breastmilk, except in premature infants and the immediate neonatal period, when there may be greater intestinal permeability.

A similar LHRH analogue, buserelin is excreted in breastmilk in negligible or undetectable amounts and did not cause hormonal alterations in infants breastfed by mothers who were taking it ^{(Dewart 1987)}, or alterations in lactation. ^{(Fraser 1989)}

Increased prolactin has been observed in women treated with gonadorelin analogues and gonadotropins ^{(Cavagna 2005, Kamel 1994, Meldrum 1992)}, although the findings are not consistent. ^{(Chantilis 1995)}

See below the information of this related product:

• Assisted Reproductive Techniques (ART) (Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.)